Skip to main content

iBio Appoints Distinguished Biotech Leader, Elizabeth Stoner, to its Board of Directors

SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) — iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases announced today the appointment of Elizabeth Stoner, M.D., M.S. to its Board of Directors. Dr. Stoner is appointed as an independent member of the Board of Directors and as a member of the Compensation Committee, following the transition of Eef Schimmelpennink from this position, who has stepped down from the Board. “We are excited to welcome Liz to our Board of Directors at a pivotal moment in iBio’s evolution as clinical-staged company,” said Martin Brenner, Ph.D., DVM, Chief Executive Officer and Chief Scientific Officer. “Liz brings decades of research and development leadership, with experience advancing programs globally and building companies from early...

Continue reading

Treace Medical Concepts Reports First Quarter 2026 Financial Results

PONTE VEDRA, Fla., May 08, 2026 (GLOBE NEWSWIRE) — Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today reported financial results for the first quarter ended March 31, 2026. Recent HighlightsGenerated revenue of $47.2 million in first quarter 2026 compared to $52.6 million in the same period in 2025.  Reported first quarter 2026 net loss of $(18.0) million and adjusted EBITDA of $(5.5) million in the first quarter 2026. Cash, cash equivalents, and marketable securities totaled $51.9 million as of March 31, 2026, representing an increase of $3.5 million from the Company’s balance of $48.4 million as of December 31, 2025, and compares to an increase of...

Continue reading

OXB to exhibit and present at the 30th Annual Meeting of the American Society of Cell and Gene Therapy (ASGCT)

Oxford, UK – 8 May 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces its participation in the 30th Annual Meeting of the American Society of Cell and Gene Therapy (ASGCT), taking place from 11-15 May in Boston. OXB will exhibit at Booth #1331, where its commercial team will be available to discuss how OXB supports the development and manufacture of cell and gene therapies from pre-clinical through to commercialisation. Representing OXB onsite will be Sébastien Ribault, PhD, Chief Business Officer, alongside Business Development Directors Mark Marrano, Lisa Parenteau, and Shyamali Mandal, PhD. In addition, OXB will contribute to the conference’s scientific program through a workshop, an industry symposium, three oral presentations, and seven poster presentations spanning automation in...

Continue reading

Aegon announces final results of tender offers for five series of subordinated notes in EUR 380 million notional

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OF AMERICA OR THE DISTRICT OF COLUMBIA (THE UNITED STATES) OR IN OR INTO ANY OTHER JURISDICTION OR TO ANY OTHER PERSON WHERE OR TO WHOM IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS DOCUMENT.  Schiphol, May 8, 2026 – Aegon (the Offeror) announces today the results of its invitation to holders of its EUR 950,000,000 Perpetual Capital Securities, ISIN: NL0000116150 (the 2004 EUR Notes), USD 500,000,000 Perpetual Capital Securities, ISIN: NL0000116168 (the 2004 USD Notes), NLG 250,000,000 Perpetual Cumulative Subordinated Bonds 1995, ISIN: NL0000120004 (the 1995 NLG Notes), NLG 300,000,000 Perpetual Cumulative Subordinated Bonds 1996, ISIN:...

Continue reading

Results of the initial public offering of Liven AS shares

The initial public offering of the shares of Liven AS (registry code: 12619609, hereinafter Liven) ended on 7 May 2026. Up to 1,495,730 new ordinary shares were publicly offered and certain minority shareholders of Liven offered up to 369,015 existing ordinary shares, up to 1,864,745 shares in total (Offer Shares). Liven reserved the right, in case of oversubscription, to increase the number of shares on offer by up to 854,705 additional new issued ordinary shares. During the offering, 2,421 investors subscribed for a total of 1,053,936 shares for EUR 4.68 each, for a total amount of EUR 4,932,420, representing 57% of the Offer Shares. 95% of the investors who participated in the offering were from Estonia. “We would like to thank all the investors who considered us a worthy investment. The result is sufficient to allow us to proceed with...

Continue reading

SATO’s employee experience strengthened – positive effects visible in customers’ everyday lives

SATO Corporation, Press release 8 May, 2026 at 2 pm SATO employees are more satisfied with their workplace than ever before. According to the latest survey results, employees value the warm and relaxed atmosphere of their work community, as well as approachable colleagues. The employee Net Promoter Index (eNPS*) was exceptionally high at 67.“According to the results, our employees appreciate exactly the things we have been building consistently over the long term: trustworthy and smooth collaboration, a humane culture and work life aligned with our values. The results show that we have done many things right,” says SATO’s CEO Antti Aarnio. According to Aarnio, employee satisfaction is also strongly reflected in the customer experience and the quality of customer service. “When employees feel well and collaboration works smoothly, it...

Continue reading

Essent Group Ltd. Announces First Quarter 2026 Results and Declares Quarterly Dividend

HAMILTON, Bermuda, May 08, 2026 (GLOBE NEWSWIRE) — Essent Group Ltd. (NYSE: ESNT) today reported net income for the quarter ended March 31, 2026 of $171.8 million or $1.82 per diluted share, compared to $175.4 million or $1.69 per diluted share for the quarter ended March 31, 2025. Essent also announced today that its Board of Directors has declared a quarterly cash dividend of $0.35 per common share. The dividend is payable on June 10, 2026 to shareholders of record on June 1, 2026. “We are pleased with our first quarter 2026 financial results, which continued to benefit from favorable credit trends and the impact of interest rates on both persistency and investment income,” said Mark A. Casale, Chairman and Chief Executive Officer. “The strong cash flow generation from our core mortgage insurance business and the strength of our...

Continue reading

ANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial Guidance

Quarterly net revenues of $237.5 million, an increase of 20.5% year-over-year Purified Cortrophin® Gel net revenues of $75.1 million, an increase of 42.1% year-over-year Quarterly GAAP net income available to common shareholders of $29.5 million; Quarterly adjusted non-GAAP EBITDA of $63.0 million, an increase of 24.1% year-over-year Diluted GAAP income per share of $1.28 and adjusted non-GAAP diluted earnings per share of $2.05 Raised 2026 total net revenue guidance to $1,080 million to $1,140 million, adjusted non-GAAP EBITDA to $285 million to $300 million, and adjusted non-GAAP diluted earnings per share to $9.19 to $9.69; reaffirmed 2026 Cortrophin Gel net revenue guidance of $540 million to $575 million $100 million share repurchase program authorized by Board of DirectorsPRINCETON, N.J., May 08, 2026 (GLOBE NEWSWIRE) —...

Continue reading

Castellum Announces First Quarter 2026 Financial Results

Revenue Increase of 23% Driven by Ramp Up of Long-Term Contracts Won in 2025; Enters Second Quarter with a Record Backlog of $273.3 Million VIENNA, Va., May 08, 2026 (GLOBE NEWSWIRE) — Castellum, Inc. (NYSE-American: CTM) (“Castellum” “CTM”, “we” or the “Company”), a cybersecurity, electronic warfare, and software services company focused on the federal government, today announced its financial results for the three-month period (“Q1”) ended March 31, 2026. Q1 2026 Financial HighlightsRevenues of $14.3 million, up 23% as compared to $11.7 million in Q1 2025. Gross profit of $5.1 million, up 11% as compared to $4.6 million in Q1 2025. Adjusted EBITDA* was $0.4 million, compared to $0.08 million in Q1 2025. Net loss was $0.4 million (or $0.00 per basic and diluted share), improved from a net loss of $1.2 million (or $0.01 per basic...

Continue reading

Brookfield Business Corporation Reports Strong First Quarter 2026 Results

BROOKFIELD, NEWS, May 08, 2026 (GLOBE NEWSWIRE) — Brookfield Business Corporation (NYSE, TSX: BBUC) announced today financial results for the quarter ended March 31, 2026. “Three things defined our quarter,” said Anuj Ranjan, CEO of Brookfield Business Corporation. “Clarios received $1 billion of cash tax credits, with similar amounts expected annually through the end of the decade. We sold a 27% interest in La Trobe, generating a 3x multiple of our original investment only four years after acquiring it. We also committed $500 million with our partners alongside OpenAI in The OpenAI Deployment Company, a new platform built to deploy enterprise AI inside real operating businesses.” He added, “We run a simple business: we buy, build, and operate essential industrial and services companies with a goal...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.